Tissue Factor and VEGF Expression in Prostate Carcinoma: A Tissue Microarray Study

REFERENCES

• Nelen V. Epidemiology of prostate cancer. Recent Results Cancer Res 2007; 175: 1–8
   PubMedGoogle Scholar
• Stewart R. J., Panigrahy D., Flynn E., Folkman J. Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J Urol 2001; 165: 688–693
   PubMed Web of Science ®Google Scholar
• Lissbrant I.F., Lissbrant E., Damber J. E., Bergh A. Blood vessels are regulators of growth, diagnostic markers and therapeutic targets in prostate cancer. Scand J Urol Nephrol 2001; 35: 437–452
   PubMed Web of Science ®Google Scholar
• Carmeliet P. Biomedicine. Clotting factors build blood vessels. Science 2001; 293: 1602–1604
   PubMed Web of Science ®Google Scholar
• Zhang Y., Deng Y., Luther T., Muller M., Ziegler R., Waldherr R., Stern D. M., Nawroth P. P. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 1994; 94: 1320–1327
   PubMed Web of Science ®Google Scholar
• Rickles F.R., Patierno S., Fernandez P. M. Tissue factor, thrombin, and cancer. Chest 2003; 124: 58S–68S
   PubMed Web of Science ®Google Scholar
• Nakasaki T., Wada H., Shigemori C., Miki C., Gabazza E. C., Nobori T., Nakamura S., Shiku H. Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer. Am J Hematol 2002; 69: 247–254
   PubMed Web of Science ®Google Scholar
• Ohta S., Wada H., Nakazaki T., Maeda Y., Nobori T., Shiku H., Nakamura S., Nagakawa O., Furuya Y., Fuse H. Expression of tissue factor is associated with clinical features and angiogenesis in prostate cancer. Anticancer Res 2002; 22: 2991–2996
   PubMed Web of Science ®Google Scholar
• Poon R.T., Lau C. P., Ho J. W., Yu W. C., Fan S. T., Wong J. Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma. Clin Cancer Res 2003; 9: 5339–5345
   PubMed Web of Science ®Google Scholar
• Lopez-Pedrera C., Barbarroja N., Dorado G., Siendones E., Velasco F. Tissue factor as an effector of angiogenesis and tumor progression in hematological malignancies. Leukemia 2006; 20: 1331–1340
   PubMed Web of Science ®Google Scholar
• Akashi T., Furuya Y., Ohta S., Fuse H. Tissue factor expression and prognosis in patients with metastatic prostate cancer. Urology 2003; 62: 1078–1082
   PubMed Web of Science ®Google Scholar
• Khorana A.A., Ahrendt S. A., Ryan C. K., Francis C. W., Hruban R. H., Hu Y. C., Hostetter G., Harvey J., Taubman M. B. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res 2007; 13: 2870–2875
   PubMed Web of Science ®Google Scholar
• Bao B. Y., Yao J., Lee Y. F. 1alpha, 25-dihydroxyvitamin d3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis 2006; 27: 1883–1893
   PubMed Web of Science ®Google Scholar
• Huang J., Yao J. L., Zhang L., Bourne P. A., Quinn A. M., di Sant'Agnese P.A., Reeder J. E. Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer. Am J Pathol 2005; 166: 1807–1815
   PubMed Web of Science ®Google Scholar
• Rush D.S., Tan J., Baergen R. N., Soslow R. A. H-caldesmon, a novel smooth muscle-specific antibody, distinguishes between cellular leiomyoma and endometrial stromal sarcoma. Am J Surg Pathol 2001; 25: 253–258
   PubMed Web of Science ®Google Scholar
• Browder T., Folkman J., Pirie-Shepherd S. The hemostatic system as a regulator of angiogenesis. J Biol Chem 2000; 275: 1521–1524
   PubMed Web of Science ®Google Scholar
• Yu J.L., May L., Klement P., Weitz J. I., Rak J. Oncogenes as regulators of tissue factor expression in cancer: implications for tumor angiogenesis and anti-cancer therapy. Semin Thromb Hemost 2004; 30: 21–30
   PubMed Web of Science ®Google Scholar
• George J., Gondi C. S., Dinh D. H., Gujrati M., Rao J. S. Restoration of tissue factor pathway inhibitor-2 in a human glioblastoma cell line triggers caspase-mediated pathway and apoptosis. Clin Cancer Res 2007; 13: 3507–3517
   Google Scholar
• Guo H., Lin Y., Zhang H., Liu J., Zhang N., Li Y., Tang Q., Kong D., Ma D. Tissue factor pathway inhibitor-2 was repressed by cpg hypermethylation through inhibition of klf6 binding in highly invasive breast cancer cells. BMC Mol Biol 2007; 8: 110
   PubMedGoogle Scholar
• Sierko E., Wojtukiewicz M. Z., Kisiel W. The role of tissue factor pathway inhibitor-2 in cancer biology. Semin Thromb Hemost 2007; 33: 653–659
   PubMed Web of Science ®Google Scholar
• Wong C.M., Ng Y. L., Lee J. M., Wong C. C., Cheung O. F., Chan C. Y., Tung E. K., Ching Y. P., Ng I. O. Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma. Hepatology 2007; 45: 1129–1138
   PubMed Web of Science ®Google Scholar
• Abdulkadir S.A., Carvalhal G. F., Kaleem Z., Kisiel W., Humphrey P. A., Catalona W. J., Milbrandt J. Tissue factor expression and angiogenesis in human prostate carcinoma. Hum Pathol 2000; 31: 443–447
   PubMed Web of Science ®Google Scholar
• Kaushal V., Mukunyadzi P., Siegel E. R., Dennis R. A., Johnson D. E., Kohli M. Expression of tissue factor in prostate cancer correlates with malignant phenotype. Appl Immunohistochem Mol Morphol 2008; 16: 1–6
   PubMedGoogle Scholar
• Delves G. H., Stewart A. B., Cooper A. J., Lwaleed B. A. Prostasomes, angiogenesis, and tissue factor. Semin Thromb Hemost 2007; 33: 75–79
   PubMed Web of Science ®Google Scholar
• Ruf W. Redundant signaling of tissue factor and thrombin in cancer progression?. J Thromb Haemost 2007; 5: 1584–1587
   PubMed Web of Science ®Google Scholar
• Hjortoe G. M., Petersen L. C., Albrektsen T., Sorensen B. B., Norby P. L., Mandal S. K., Pendurthi U. R., Rao L. V. Tissue factor-factor VIIa-specific up-regulation of il-8 expression in mda-mb-231 cells is mediated by par-2 and results in increased cell migration. Blood 2004; 103: 3029–3037
   PubMed Web of Science ®Google Scholar
• Staton C.A., Chetwood A. S., Cameron I. C., Cross S. S., Brown N. J., Reed M. W. The angiogenic switch occurs at the adenoma stage of the adenoma carcinoma sequence in colorectal cancer. Gut 2007; 56: 1426–1432
   PubMed Web of Science ®Google Scholar
• Abraham E., Reinhart K., Opal S., Demeyer I., Doig C., Rodriguez A. L., Beale R., Svoboda P., Laterre P. F., Simon S., Light B., Spapen H., Stone J., Seibert A., Peckelsen C., De Deyne C., Postier R., Pettila V., Artigas A., Percell S. R., Shu V., Zwingelstein C., Tobias J., Poole L., Stolzenbach J. C., Creasey A. A. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003; 290: 238–247
   PubMed Web of Science ®Google Scholar
• Laterre P. F., Wittebole X., Collienne C. Pharmacological inhibition of tissue factor. Semin Thromb Hemost 2006; 32: 71–76
   PubMed Web of Science ®Google Scholar
• Ohsawa M., Koyama T., Yamamoto K., Hirosawa S., Kamei S., Kamiyama R. 1alpha,25-dihydroxyvitamin d(3) and its potent synthetic analogs downregulate tissue factor and upregulate thrombomodulin expression in monocytic cells, counteracting the effects of tumor necrosis factor and oxidized ldl. Circulation 2000; 102: 2867–2872
   PubMed Web of Science ®Google Scholar
• Tenno T., Oberg F., Mackman N., Nilsson K., Siegbahn A. Pml/raralpha plays a role for basal activity and retinoid-induced repression of the tissue factor promoter in acute promyelocytic leukemia cells. Thromb Haemost 2003; 90: 930–939
   PubMed Web of Science ®Google Scholar
• Ma Q., Tobu M., Schultz C., Jeske W., Hoppensteadt D., Walenga J., Cornelli U., Lee J., Linhardt R., Hanin I., Fareed J. Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides. Thromb Res 2007; 119: 653–661
   PubMed Web of Science ®Google Scholar
• Hembrough T. A., Swartz G. M., Papathanassiu A., Vlasuk G. P., Rote W. E., Green S. J., Pribluda V. S. Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Cancer Res 2003; 63: 2997–3000
   PubMed Web of Science ®Google Scholar